JP2022541550A5 - - Google Patents
Info
- Publication number
- JP2022541550A5 JP2022541550A5 JP2022503463A JP2022503463A JP2022541550A5 JP 2022541550 A5 JP2022541550 A5 JP 2022541550A5 JP 2022503463 A JP2022503463 A JP 2022503463A JP 2022503463 A JP2022503463 A JP 2022503463A JP 2022541550 A5 JP2022541550 A5 JP 2022541550A5
- Authority
- JP
- Japan
- Prior art keywords
- level
- upper limit
- less
- pharmaceutical composition
- reference range
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962876176P | 2019-07-19 | 2019-07-19 | |
| US62/876,176 | 2019-07-19 | ||
| US202063047822P | 2020-07-02 | 2020-07-02 | |
| US63/047,822 | 2020-07-02 | ||
| PCT/US2020/042820 WO2021016208A1 (en) | 2019-07-19 | 2020-07-20 | Methods of treating congenital adrenal hyperplasia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022541550A JP2022541550A (ja) | 2022-09-26 |
| JP2022541550A5 true JP2022541550A5 (https=) | 2023-07-28 |
Family
ID=74193935
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022503463A Pending JP2022541550A (ja) | 2019-07-19 | 2020-07-20 | 先天性副腎過形成を処置する方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20220133742A1 (https=) |
| EP (1) | EP3986416A4 (https=) |
| JP (1) | JP2022541550A (https=) |
| KR (1) | KR20220052927A (https=) |
| CN (1) | CN114423436A (https=) |
| AU (1) | AU2020318970B2 (https=) |
| BR (1) | BR112022000956A2 (https=) |
| CA (1) | CA3147891A1 (https=) |
| MX (1) | MX2022000812A (https=) |
| TW (1) | TW202116324A (https=) |
| WO (1) | WO2021016208A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS65839B1 (sr) | 2014-01-21 | 2024-09-30 | Neurocrine Biosciences Inc | Crf1 receptor antagonisti za tretman kongenitalne adrenalne hiperplazije |
| WO2019036503A1 (en) | 2017-08-14 | 2019-02-21 | Spruce Biosciences, Inc. | CORTICOTROPIN RELEASE FACTOR RECEPTOR ANTAGONISTS |
| EP4643950A3 (en) | 2018-04-27 | 2026-01-14 | Spruce Biosciences, Inc. | Methods for treating testicular and ovarian adrenal rest tumors |
| US20220023266A1 (en) | 2018-12-07 | 2022-01-27 | Neurocrine Biosciences, Inc. | Crf1 receptor antagonist, pharmaceutical formulations and solid forms thereof for the treatment of congenital adrenal hyperplasia |
| JP7623365B2 (ja) | 2019-09-27 | 2025-01-28 | ニューロクライン バイオサイエンシーズ，インコーポレイテッド | Ｃｒｆ受容体アンタゴニストおよび使用方法 |
| KR20240023691A (ko) * | 2020-08-12 | 2024-02-22 | 스프루스 바이오사이언시스 인코포레이티드 | 다낭성 난소 증후군을 치료하기 위한 방법 및 조성물 |
| US20240024330A1 (en) * | 2020-08-26 | 2024-01-25 | Neurocrine Biosciences, Inc. | Crf receptor antagonists and methods of use |
| MD20210019A2 (ro) | 2021-04-12 | 2022-10-31 | Максим МАСЮТИН | Metodă de tratament a hiperplaziei suprarenale congenitale, cauzate de deficit de 21-hidroxilază cu debut tardiv prin regimul de glucocorticoizi adaptat individual |
| JP2024539907A (ja) * | 2021-11-19 | 2024-10-31 | スプルース バイオサイエンシーズ，インク． | チルダセルフォントの結晶性組成物ならびにその使用方法および調製方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050085479A1 (en) * | 2003-08-27 | 2005-04-21 | Pharmacia Corporation | Mediated central nervous system compositions of a cyclooxygenase-2 selective inhibitor and a corticotropin releasing factor antagonist for the treatment of ischemic disorders or injury |
| EP1708790B1 (en) * | 2003-12-02 | 2010-04-21 | PharmaNeuroBoost N.V. | Use of pipamperone and a d2-receptor antagonist or a serotonin/dopamin antagonist for the treatment of psychotic disorders |
| CN101516835A (zh) * | 2006-07-19 | 2009-08-26 | 俄亥俄州立大学研究基金会 | 选择性雄激素受体调节剂、它们的类似物和衍生物以及它们的用途 |
| HRP20100516T1 (hr) * | 2006-09-20 | 2010-10-31 | Eli Lilly And Company | Tiazolpirazolopirimidini kao antagonisti receptora crf1 |
| US20150094310A1 (en) * | 2012-04-23 | 2015-04-02 | Holsboermaschmeyer Neurochemie Gmbh | Crhr1 antagonists for use in the treatment of patients having crh overactivity |
| RS65839B1 (sr) * | 2014-01-21 | 2024-09-30 | Neurocrine Biosciences Inc | Crf1 receptor antagonisti za tretman kongenitalne adrenalne hiperplazije |
| JP7285222B2 (ja) * | 2017-08-14 | 2023-06-01 | スプルース バイオサイエンシズ インコーポレイテッド | 副腎皮質刺激ホルモン放出因子受容体拮抗薬 |
| WO2019036503A1 (en) * | 2017-08-14 | 2019-02-21 | Spruce Biosciences, Inc. | CORTICOTROPIN RELEASE FACTOR RECEPTOR ANTAGONISTS |
| EP4643950A3 (en) * | 2018-04-27 | 2026-01-14 | Spruce Biosciences, Inc. | Methods for treating testicular and ovarian adrenal rest tumors |
| US20220023266A1 (en) * | 2018-12-07 | 2022-01-27 | Neurocrine Biosciences, Inc. | Crf1 receptor antagonist, pharmaceutical formulations and solid forms thereof for the treatment of congenital adrenal hyperplasia |
-
2020
- 2020-07-20 JP JP2022503463A patent/JP2022541550A/ja active Pending
- 2020-07-20 AU AU2020318970A patent/AU2020318970B2/en active Active
- 2020-07-20 WO PCT/US2020/042820 patent/WO2021016208A1/en not_active Ceased
- 2020-07-20 CN CN202080065892.7A patent/CN114423436A/zh active Pending
- 2020-07-20 BR BR112022000956A patent/BR112022000956A2/pt unknown
- 2020-07-20 TW TW109124484A patent/TW202116324A/zh unknown
- 2020-07-20 MX MX2022000812A patent/MX2022000812A/es unknown
- 2020-07-20 KR KR1020227005252A patent/KR20220052927A/ko active Pending
- 2020-07-20 CA CA3147891A patent/CA3147891A1/en active Pending
- 2020-07-20 EP EP20844541.1A patent/EP3986416A4/en active Pending
-
2022
- 2022-01-18 US US17/578,149 patent/US20220133742A1/en active Pending
-
2024
- 2024-02-09 US US18/438,060 patent/US20240261300A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022541550A5 (https=) | ||
| JP2025020148A5 (https=) | ||
| IL286048B2 (en) | Abiraterone decanoate and its pharmaceutical salts, pharmaceutical preparations containing them, their uses and preparation | |
| Africander et al. | Molecular mechanisms of steroid receptor-mediated actions by synthetic progestins used in HRT and contraception | |
| Sitruk-Ware et al. | Nestorone®: clinical applications for contraception and HRT | |
| Sitruk-Ware | New progestogens: a review of their effects in perimenopausal and postmenopausal women | |
| Regidor et al. | Antiandrogenic and antimineralocorticoid health benefits of COC containing newer progestogens: dienogest and drospirenone | |
| Sitruk-Ware et al. | The use of newer progestins for contraception | |
| JP2656958B2 (ja) | ホルモン依存性腫瘍治療剤 | |
| CA2326654A1 (en) | Use of steroidal alkaloid derivatives as inhibitors of hedgehog signaling pathways | |
| CN1075375C (zh) | 合并应用于女性避孕的具黄体酮拮抗作用和抗雌激素作用的化合物 | |
| JP2007535922A5 (https=) | ||
| JP2006527193A5 (https=) | ||
| JP2011502172A5 (https=) | ||
| WO2011049948A4 (en) | Neuroprotection and myelin repair using nestorone® | |
| JP2010507685A (ja) | 子宮内膜増殖を抑制するための組成物および方法 | |
| JP2021512852A5 (https=) | ||
| CN103298343A (zh) | 类固醇和糖皮质激素受体拮抗剂组合疗法 | |
| Davtyan | Four generations of progestins in oral contraceptives | |
| JP2008534533A5 (https=) | ||
| JP2018062530A (ja) | プロゲステロン依存性病態を処置する方法およびその組成物 | |
| WO2023163945A1 (en) | Treatment of congenital adrenal hyperplasia and polycystic ovary syndrome | |
| Noori et al. | Effects of estrogen and progesterone used in oral contraceptive pills: A review | |
| JP2005513024A5 (https=) | ||
| IL312515A (en) | Bispecific cd16a binders |